reports
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON to Provide Corporate Progress Updates at Several Events in Marc...
ORYZON to Provide Corporate Progress Updates at Several Events in March-April BIO-Europe Spring 2025Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in March-April. Oryzon will attend the Bio-Europe Spring 2025, which will be held...
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS...
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat A non-interventional study published in Frontiers in PsychiatryPsychometric profile characterization of 30 subjects with Phelan-McDermid Syndrome (PMS), defining three distinct subsetsStudy provides clinical scales and thresholds for patient selection in future clinical trials, based on aggressiveness, cognition, and behavioral traitsConducted in collaboration with the Medical and Molecular Genetics Institute (INGEMM) ...
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression ...
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)CAB and Oryzon establish primary and key secondary endpoints for Phase III trial, aligned with FDA standardsOryzon moves forward with plans to submit Phase III protocol to the FDA in 1H 2025 MADRID and CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, O...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Announces the Voting Results of February 2025 Extraordinary Gen...
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting All resolutions were approved MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for diseases with significant unmet medical needs, today announced the results of voting at the Extraordinary General Shareholders' Meeting held today in Madrid. A total of 24,030,812 of the Company's issued and outstanding ordinary shares (representing 36.5312% of the share ...
ORYZON Reports Financial Results and Corporate Update for Quarter Ende...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024 Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreachPreparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in Borderline Personality Disorder ongoing Final data from REIMAGINE proof-of-concept Phase IIa trial published in Psychiatry and Clinical NeurosciencesContinues to enroll patients in Phase IIb EVOLUTION trial with vafidemstat in schizophreniaFirst patients dosed in Investigator-initiated Phase I study of iadade...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Resu...
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (ADHD) and autistic spectrum disorder (ASD) Vafidemstat demonstrated a relevant clinical benefit in reducing agitation/aggression across all studied patient populations Data was seminal to start further clinical development in BPDAfter an informative Phase IIb in BPD...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’...
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces significant changes to its Board of Directors at the upcoming Shareholders' Meeting, scheduled for February 28. Four new members will be add...
ORYZON announces first patient dosed in an Investigator-initiated Phas...
ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in an investigator-initiated Phase I dose-finding trial of iadademstat, Oryzon’s p...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Bu...
ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor MADRID, Spain and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, is pleased to announce the appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor. Dr. Beaurang has over 25 years of experience in biotechnology focusing on corporate strategy, business development, oncology, immunolo...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in C...
ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia Study conducted under the CRADA agreement between NCI and Oryzon MADRID, Spain and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in a Phase I dose-finding clinical trial of iadademstat...
ORYZON to Provide Corporate Progress Updates at Several Events in Janu...
ORYZON to Provide Corporate Progress Updates at Several Events in January-February 8th Sachs Annual Neuroscience Innovation Forum14th Annual LifeSci Advisors Corporate Access EventInvest Securities BioMed Forum 2025MidCap Events Frankfurt 2025Bio-Neuroscience 2025 MADRID and CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progre...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.